In real-world patients with subjective cognitive impairment (SCC) and mild cognitive impairment (MCI), blood biomarkers for Alzheimer’s disease (AD) and neurodegeneration correlate with underlying pathology, but contribute only little to 5-year models for dementia risk prediction.
